血清CEA、CA19-9、CA50联检对早期非小细胞肺癌的诊断价值

目的通过对癌胚抗原(CEA)、糖类抗原50(CA50)、胃肠道癌抗原(CA19-9)肿瘤标志物的联合检测(TM)的方法,探讨TM对早期非小细胞肺癌(NSCLC)的诊断相关性。寻找提高早期非小细胞肺癌诊断阳性率的最佳手段。方法对82例早期非小细胞肺癌患者在治疗前通过血清CEA、CA50、CA19-9进行单检和联检。结果早期非小细胞肺癌血清中3种TM含量明显高于对照组,差异有统计学意义(P<0.01),血清CEA+CA50+CA19-9联检早期非小细胞肺癌阳性率可达87.80%,明显高于单检(P<0.01)。结论联检血清CEA+CA50+CA19-9可提高早期非小细胞肺癌诊断的阳性率,对早期非小细胞肺癌的诊断具有重要价值。

Diagnostic value of combined detection of serum CEA, CA50 and CA19-9 in early non-small cell lung cancer

Objective To explore the diagnostic value of combined detection of serum tumor markers including carcinoembryonic antigen (CEA),carbohydrate antigen 50 (CA50) and carbohydrate antigen 19-9 (CA19-9) in early non-small cell lung cancer (NSCLC),and seek for the optimal means improving the diagnostic rate of NSCLC.Methods The single and combined detection of serum CEA,CA50 and CA19-9 were carried out for 82 patients with NSCLC after treatment.Results The contents of three tumor markers (CEA,CAS0 and CA19-9) were significantly higher in NSCLC group than those in healthy control group.The difference was statistically significant (P<0.01).The positive rate of combined detection of CEA,CA50 and CA19-9 accounted for 87.80% in diagnosing early NSCLC,markedly higher than that of single detection (P<0.01).Conclusion Combined detection of CEA,CA50 and CA19-9 improves the diagnostic rate of early NSCLC,and plays an important role in the diagnosis of early NSCLC.